Navigation Links
Scientists Identify the Most Significant Single Predictor of Aggressive Prostate Cancer

An elevated rate of increase in prostate specific antigen (PSA) levels is the most significant predictor of aggressive form of prostate cancer, according to a new study published in the journal Cancer.

The study suggests if the rate of PSA increase prior to treatment (PSA Velocity) is more than 2 ng/ml/year, it is an indication of a high risk of death from prostate cancer.

According to the researchers, the new findings attain significance with recent studies suggesting that factors like microscopic features of the tumour (Gleason score), and size, spread and location of the disease are not very effective to determine prognosis.

Dr. Anthony DAmico of Bostons Brigham and Womens Hospital and colleagues characterised PSA velocity significant in prostate cancer-specific mortality (PCSM) rates following treatment with radical prostatectomy (RP) or radiation therapy (RT).

The researchers reviewed data from 948 men with localized prostate cancer who had one or more high-risk factors, and found that PSA velocity appeared to be the most important single prognostic factor. They observed that men who had multiple risk factors died from their disease significantly earlier than those who had only one factor.

Among men who underwent treatment with RP or RT, 44 per cent and 28 per cent, respectively, had pre-treatment PSA velocities of 2 ng/ml/year as their only identified high-risk factor.

It was observed that of those men who died with only one identified high-risk factor, 88 per cent of RP-treated patients and 80 per cent of RT-treated patients had pre-treatment PSA velocities of 2 ng/ml/year.

The study authors have also pointed out at the results of various other studies that have shown that the time to death shortens as PSA velocity increases, which suggests that further research should examine using stratified PSA velocities to assess risk in men with localised disease.

"These findings hi ghlight the ability of a pre-treatment PSA velocity 2 ng/ml/year alone to identify men with aggressive prostate cancer and in whom effective systemic treatment in addition to mono-therapy with RP or RT is needed to decrease PCSM rates," conclude the authors.


'"/>




Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. Scientists found ancient Human Germ Killer
3. Scientists locate key hormone involved in appetite control
4. Scientists open the book of life
5. Scientists review SARS
6. Scientists crack dengue fever puzzle
7. Scientists push to lower hidden sodium in food
8. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
9. Scientists have found effective brain regions for deep brain stimulation for Parkinson’s
10. Scientists reveal the secrets of sarcasm
11. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology: